A Randomised, Double Blind, Placebo-controlled, Multiple Dose Trial of Anti-IL-20 (109-0012) in Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Fletikumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 15 Jun 2013 Patient-reported outcomes presented at the 14th Annual Congress of the European League Against Rheumatism.
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History